Pantherna Therapeutics raises €4.0M Series A round
11 January 2022· Hennigsdorf, Germany· health, biotech, materials, b2b, deep_hardware
Proceeds will be used to accelerate preclinical development activities for the lead program PAN004, expand development efforts, and strengthen the R&D team to advance mRNA therapeutics for new indications.
Investors
LeadRiesner Verwaltungs GmbH
Also participating
High-Tech Gründerfonds
About Pantherna Therapeutics
Stage
Series A
Headquarters
Hennigsdorf, Germany
Founded
2017
Team Size
6–20
Sectors
healthbiotechmaterialsb2bdeep_hardware